{"ok":true,"nota":{"id":"2544b94d551a3771","slug":"un-tipo-de-enzima-aparece-mas-en-tumores-de-vejiga-y-se-asocia-con-una-2544b9","titulo":"Un tipo de enzima aparece más en tumores de vejiga y se asocia con una sobrevida más corta","resumen":"Analizaron 350 casos de cáncer de vejiga y midieron cuánta proteína SETDB1 tenía cada tumor. Los pacientes con más expresión de esta proteína tuvieron peor sobrevida global.","fuente":"biorxiv","fuenteNombre":"bioRxiv · preprints","color":"#be2628","autor":"Athans, S. R., Young, M., Yu, H., Doshi, B., Karasik, E., Ueshima, S., Fang, J., Woloszynska-Read, A.","url":"https://www.biorxiv.org/content/10.64898/2026.10.23.761403v1?rss=1","imagen":"/hoy/portada/2544b94d551a3771","tema":"salud","subtemas":["cáncer de vejiga","pronóstico","biomarcadores","oncología","epigenética"],"entidades":["bioRxiv","SETDB1"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-27T00:00:00.000Z","indexTs":"2026-10-27T16:14:26.625Z","hash":"f2fe8182a4b7ae510080293c87ef3f85bccbbdc05bfe0d28cad12d122df7b59b","tsa":{"time":"Oct 27 16:15:37 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Si un análisis de tejido indica qué tumores son más agresivos, los médicos pueden ajustar el seguimiento y el tratamiento con más criterio. Este dato sugiere que SETDB1 podría servir como marcador de pronóstico y también como posible blanco de futuros fármacos. Pero es una asociación observada en un grupo de pacientes: no prueba que la proteína cause la peor evolución.","quienFirma":"Universidad no identificada en el resumen (preprint en bioRxiv)","confianza":"preprint","consulta":null},"sello":{"hash":"f2fe8182a4b7ae510080293c87ef3f85bccbbdc05bfe0d28cad12d122df7b59b","sello":"18fe9247bc2b1a43c1126b2c3a485a2d199cb8ad85c597f1edeb664b580179fb","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6589557,"aleatorio":"074102cb3486d8030e85bccc146ee3d40bd144f9cae3dc815e4783f75ca0035b","tiempo":"2026-10-27T16:15:30.000Z"},"nist":{"cadena":2,"pulso":2001772,"salida":"0E703280D2ECB99CF237148891BE4B05125CA4A9FA93BA99C93DE108693398FC1C1436A917C2E942D3FD99D4FACCDDC40E70589522F4EEDE9B18514294B0BD55","tiempo":"2026-10-27T12:55:00.000Z"},"noAntes":"2026-10-27T16:15:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 27 16:15:37 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Tumor SETDB1 expression predicts worse overall survival for bladder cancer patients","descripcion":"Aberrant activity of histone methyltransferases promotes tumorigenesis across multiple cancer types, making this class of enzymes attractive therapeutic targets. The histone methyltransferase SETDB1 is frequently amplified in bladder cancer and has been implicated in chemotherapy resistance. We examine whether SETDB1 protein expression is associated with overall survival and tumor characteristics in bladder cancer. To assess SETDB1 protein expression in patients, we performed immunohistochemistry in tissue microarrays (TMAs) containing 350 bladder cancer cases with well-annotated clinical information. Digital image analysis was used to quantify SETDB1 protein expression to produce a SETDB1 H","pubDate":"2026-10-27","url":"https://www.biorxiv.org/content/10.64898/2026.10.23.761403v1?rss=1"},"indexado":"2026-10-27T16:14:26.625Z"}}